Based on promising in vitro data, they are administered intratracheally and intraperitoneally in a mouse bleomycin model, assessing their ability to decrease alveolar inflammation, lung fibrosis, collagen deposition, and TGF‐β expression. Here, TGFB1 is linked to pulmonary fibrosis.